These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31442475)

  • 21. [Clinical significance of new classification of gastroenteropancreatic neuroendocrine neoplasms].
    Zhu XZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jan; 16(1):12-4. PubMed ID: 23691561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Present and future of immunotherapy in Neuroendocrine Tumors".
    Albertelli M; Dotto A; Nista F; Veresani A; Patti L; Gay S; Sciallero S; Boschetti M; Ferone D
    Rev Endocr Metab Disord; 2021 Sep; 22(3):615-636. PubMed ID: 33851319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
    Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
    Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
    Xu G; Wang Y; Zhang H; She X; Yang J
    Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune oncology and neuroendocrine tumors.
    Chauhan A; Anthony L
    Ann Oncol; 2017 Sep; 28(9):2322-2323. PubMed ID: 28505259
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
    Klöppel G
    Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
    BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
    Kawasaki K; Fujii M; Sato T
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.
    Amair-Pinedo F; Matos I; Saurí T; Hernando J; Capdevila J
    Target Oncol; 2017 Dec; 12(6):757-774. PubMed ID: 29143176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
    Garcia-Alvarez A; Cubero JH; Capdevila J
    Curr Oncol Rep; 2022 Apr; 24(4):451-461. PubMed ID: 35171460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
    Delaunoit T; Van den Eynde M; Borbath I; Demetter P; Demolin G; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Van Laethem JL; Verslype C; Hendlisz A
    Acta Gastroenterol Belg; 2009; 72(1):49-53. PubMed ID: 19402372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison.
    Kasajima A; Klöppel G
    Endocr Relat Cancer; 2020 Nov; 27(11):R417-R432. PubMed ID: 33032264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Consensus and controversy of endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors].
    Chen H; Chen Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):982-986. PubMed ID: 28900987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions.
    Fang L; Arvind D; Dowlati A; Mohamed A
    J Neuroendocrinol; 2021 Mar; 33(3):e12943. PubMed ID: 33724586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.